Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Bipolar depression has limited treatment options compared to major depressive disorder.
• There is a pressing need for novel and effective therapeutic strategies.

Purpose of the Study:

• To evaluate the feasibility and safety of arketamine as an adjunct treatment for bipolar depression.
• To assess the preliminary efficacy of arketamine in reducing depressive symptoms.

Main Methods:

• A pilot study involving six subjects diagnosed with bipolar disorder types I and II in a depressive episode.
• Subjects received two intravenous infusions of arketamine (0.5 mg/kg followed by 1 mg/kg one week later).
• Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS).

Main Results:

• A significant decrease in MADRS scores was observed 24 hours after the first (0.5 mg/kg) infusion (p=0.036).
• A further significant reduction in MADRS scores occurred 24 hours after the second (1 mg/kg) infusion (p<0.001).
• Arketamine was well-tolerated, with minimal dissociation and no emergent manic symptoms.

Conclusions:

• Arketamine demonstrated rapid-acting antidepressant properties in patients with bipolar depression.
• This pilot trial suggests arketamine is a feasible and safe treatment option.
• Further research is warranted to confirm these findings in larger trials.